Conditioning Regimens for Patients With Severe Aplastic Anemia Transplanted With Marrow From an Unrelated Donor
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00144729
Recruitment Status :
First Posted : September 5, 2005
Last Update Posted : April 30, 2008
Fred Hutchinson Cancer Research Center
University of Minnesota - Clinical and Translational Science Institute
A single arm dose optimization study in which all patients are given a fixed dose of Cytoxan (4 x 50 mg/kg) plus ATG (3 x 30 mg/kg) and the TBI dose starting at 3 x 200 cGy is escalated or de-escalated dependent upon engraftment and toxicity.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
up to 55 Years (Child, Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Life-threatening marrow failure of nonmalignant etiology;
failure to respond to the best available immunosuppressive treatment;
lack of a HLA-identical family member
Severe disease other than aplastic anemia that would severly limit the probability of survival during the graft procedure;